UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported) April 2, 2008
 
ZILA, INC.
(Exact Name of Registrant as Specified in Charter)
         
Delaware   0-17521   86-0619668
(State or Other Jurisdiction of Incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
 
5227 North 7th Street, Phoenix, Arizona 85014-2800
(Address of Principal Executive Offices)
 
(602) 266-6700
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Item 5.02.   Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     On April 2, 2008, the Board of Directors of the Company approved a salary reduction program pursuant to which the following officers’ salaries were reduced by 10%:
                     
        Base Salary     Base Salary  
Name   Position   (pre-reduction)     (post-reduction)  
David R. Bethune  
Chairman and Interim Chief Executive Officer
  $ 255,000     $ 229,500  
Frank J. Bellizzi  
Executive Vice President and President of Zila Pharmaceuticals, Inc.
  $ 360,000     $ 324,000  
Gary V. Klinefelter  
Vice President, General Counsel and Secretary
  $ 240,000     $ 216,000  
Diane E. Klein  
Vice President of Finance and Treasurer
  $ 185,000     $ 166,500  
David A. Barshis  
Senior Vice President and General Manager of Zila Pharmaceuticals, Inc.
  $ 225,000     $ 202,500  
     The salary reductions described above will become effective with the pay period that begins on April 14, 2008.

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 7, 2008
         
  ZILA, INC.
 
 
  /s/ Gary V. Klinefelter    
  By:   Gary V. Klinefelter   
    Vice President and General Counsel   
 

 

Zila (NASDAQ:ZILA)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Zila Charts.
Zila (NASDAQ:ZILA)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Zila Charts.